Loading
Staphylococcus Aureus Bacteremia / Staphylococcus Aureus Septicemia / Daptomycin for Injection · Phase 4 Trial
ClinicalTrials.gov · July 31, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a planned Phase 4 open-label RCT registered on ClinicalTrials.gov comparing daptomycin and vancomycin in patients with MRSA bacteremia, with a primary endpoint of Desirability of Outcome Ranking at day 90. No results have been posted in this registry record, and the trial is currently recruiting; clinical interpretation cannot yet be made.
Phase 4, Interventional, Randomized, Parallel, Open label, Treatment purpose. Staphylococcus Aureus Septicemia, Staphylococcus Aureus Bacteremia, S. Aureus Bacteremia, S. Aureus Bloodstream Infection, Staphylococcus Aureus Endocarditis; age from 18 Years. Intervention: Daptomycin. Compared with: Vancomycin — Active Comparator. n = 300. 19 sites: Australia, Canada.
This is a planned Phase 4 open-label RCT registered on ClinicalTrials.gov comparing daptomycin and vancomycin in patients with MRSA bacteremia, with a primary endpoint of Desirability of Outcome Ranking at day 90. No results have been posted in this registry record, and the trial is currently recruiting; clinical interpretation cannot yet be made.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
This is a registry record for an ongoing Phase 4 RCT with no reported results; it describes a planned comparison of two established antibiotics for MRSA bacteremia but cannot inform clinical practice until outcomes are analysed and published.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06637332). This is a study registration, not published results. Lead sponsor: Todd C. Lee MD MPH FIDSA. Recruitment status: RECRUITING. Phase: PHASE4. Study type: INTERVENTIONAL. Enrollment: 300 participants (ESTIMATED). Conditions: Staphylococcus Aureus Septicemia, Staphylococcus Aureus Bacteremia, S. Aureus Bacteremia, S. Aureus Bloodstream Infection, Staphylococcus Aureus Endocarditis. Interventions: DRUG: Daptomycin for Injection; DRUG: Vancomycin (IV). Primary outcome measures: Desirability of Outcome Ranking (DOOR) , Day 90 post enrollment in the S. aureus Network Adaptive Platform Trial (NCT05137119). Brief summary: This is an open label randomized controlled trial for patients with methicillin resistant S. aureus (MRSA) bloodstream infection which will directly compare the two most commonly used therapies, vancomycin and daptomycin. This study is an approved sub-study of The Staphylococcus aureus Network Adaptive Platform (SNAP) trial (NCT05137119)
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.